Study identifies factors driving effectiveness of off-the-shelf CAR-T therapy
Source ↗
👁 1
💬 0
A new study, published Sept. 25 in Cancer Discovery, reveals key insights into the biological factors shaping efficacy of off-the-shelf CAR-T cell therapies. Andrew Jallouk, MD, PhD, Assistant Professor of Medicine in the Division of Hematology/Oncology, was lead author of the study.
Currently, standard CAR-T therapies require a patient’s own T cells to be collected, genetically engineered and returned to the patient — a complex process which can take several weeks. Off-the-shelf CAR-T
Currently, standard CAR-T therapies require a patient’s own T cells to be collected, genetically engineered and returned to the patient — a complex process which can take several weeks. Off-the-shelf CAR-T
Comments (0)